Moneycontrol News
Cadila Healthcare shares rallied nearly 5 percent intraday Thursday after getting zero observations from the US health regulator for Moraiya plant.
Sources told CNBC-TV18 that the US Food and Drug Administration has issued zero observations for Moraiya unit (Gujarat) after its re-inspection.
The USFDA had re-inspected this facility in 2017.
Earlier also, when the US health regulator had inspected Moraiya unit during February 6-15, 2017, it did not get any observations (483).
Cadila has been received several approvals from USFDA for drugs filed from Moraiya facility, especially since February inspection with zero observations.
At 13:10 hours IST, the stock price was quoting at Rs 514.45, up Rs 18.75, or 3.78 percent on the BSE.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
